Human serum albumin-based design of a diflunisal prodrug.
Human serum albumin-based design of a diflunisal prodrug.
复制标题
基于人血清白蛋白的二氟尼柳前药设计。
DOI:
10.1016/j.ejpb.2013.01.013
复制
发表时间:
2013-08
期刊:
影响因子:
--
通讯作者:
梁宏
中科院分区:
文献类型:
--
作者:
杨峰;梁宏
The cyclooxygenase-2 inhibitor, diflunisal, is used in the clinic for its anti-inflammatory activity. About 99% of a dose of diflunisal is unavailable for reaction with the target enzyme, because diflunisal strongly binds to human serum albumin (HSA). To reduce the binding affinity of diflunisal to albumin, we designed and synthesized the prodrug acetyldiflunisal. The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199. Mass spectrometry confirmed that acetyldiflunisal acetylates Lys199. The acetylated albumin had twofold weaker binding affinity for diflunisal as demonstrated by fluorescence quenching. Reduced binding affinity means that diflunisal is more easily released from acetylated albumin into the circulation. Therefore, lower doses of acetyldiflunisal compared to diflunisal will be required. Taken together, our results not only provide a template for design of HSA-based prodrugs, but also pave the way toward more effective use of diflunisal in the clinic.
登录
查看更多内容
影响因子:
3.7
作者:
Chatterjee T;Pal A;Dey S;Chatterjee BK;Chakrabarti P
通讯作者:
Chakrabarti P
影响因子:
7.7
作者:
G. Roberts
通讯作者:
G. Roberts
影响因子:
2.8
作者:
John P. Utz;Louis S. Goodman;Alfred Gilman
通讯作者:
John P. Utz;Louis S. Goodman;Alfred Gilman
影响因子:
5.8
作者:
Liyasova, Mariya S.;Schopfer, Lawrence M.;Lockridge, Oksana
通讯作者:
Lockridge, Oksana
影响因子:
5.6
作者:
Zunszain, Patricia A.;Ghuman, Jamie;McDonagh, Antony F.;Curry, Stephen
通讯作者:
Curry, Stephen